Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. Financials
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-09-22
30.48 CNY   -1.65%
09/13China Approves Drug Registration Application for Fosun Pharmaceutical's Anti-Schizophrenia Medication
MT
09/08Neovii and Fosun Pharma Enter into an Exclusive Agreement
AQ
09/08Shandong Liancheng Precision Manufacturing Co., Ltd entered into an agreement to acquire 3.9858% stake in Shanghai Shen-li High Tech Co., Ltd. from Shanghai Fosun Pharmaceutical Co., Ltd. and Shanghai Fulian Technology Co., Ltd. for CNY 61 million.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 65 086125 791113 86273 970--
Enterprise Value (EV)1 77 050139 217127 15089 03986 41286 971
P/E ratio 20,5x37,8x26,5x16,7x13,4x11,6x
Yield 1,47%0,80%1,14%1,66%2,06%2,36%
Capitalization / Revenue 2,28x4,15x2,92x1,64x1,47x1,33x
EV / Revenue 2,70x4,59x3,26x1,97x1,72x1,57x
EV / EBITDA 13,1x22,2x15,7x15,9x12,9x11,2x
Price to Book 2,14x3,74x3,21x1,83x1,66x1,49x
Nbr of stocks (in thousands) 2 562 8992 562 8992 562 8992 669 655--
Reference price (CNY) 26,654,048,930,530,530,5
Announcement Date 03/30/202003/29/202103/22/2022---
1 CNY in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 28 58530 30739 00545 08550 16255 566
EBITDA1 5 8746 2828 1055 5996 7137 782
Operating profit (EBIT)1 4 4944 7216 3143 6394 5695 415
Operating Margin 15,7%15,6%16,2%8,07%9,11%9,75%
Pre-Tax Profit (EBT)1 4 5264 6786 0545 6227 1328 251
Net income1 3 3223 6634 7354 0865 3066 234
Net margin 11,6%12,1%12,1%9,06%10,6%11,2%
EPS2 1,301,431,851,832,282,62
Dividend per Share2 0,390,430,560,510,630,72
Announcement Date 03/30/202003/29/202103/22/2022---
1 CNY in Million
2 CNY
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 11 95710 38210 89310 04513 08410 826
EBITDA ------
Operating profit (EBIT)1 1 6158961 8021 0201 2711 081
Operating Margin 13,5%8,63%16,5%10,2%9,71%9,99%
Pre-Tax Profit (EBT) ------
Net income ------
Net margin ------
EPS2 0,460,180,420,430,400,50
Dividend per Share ------
Announcement Date 03/22/202204/26/202208/29/2022---
1 CNY in Million
2 CNY
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 11 96413 42613 28915 06912 44213 001
Net Cash position1 ------
Leverage (Debt / EBITDA) 2,04x2,14x1,64x2,69x1,85x1,67x
Free Cash Flow1 -706-1 857-927-2 4282 5133 547
ROE (Net Profit / Equities) 11,6%10,8%12,4%9,65%11,7%12,6%
Shareholders' equity1 28 75933 79038 03742 34345 22349 654
ROA (Net Profit / Asset) 4,53%4,58%5,35%3,67%4,63%5,23%
Assets1 73 34179 90488 433111 428114 524119 126
Book Value Per Share2 12,414,415,316,718,420,5
Cash Flow per Share2 1,261,011,541,082,162,37
Capex1 3 9284 4374 8752 3882 7652 800
Capex / Sales 13,7%14,6%12,5%5,30%5,51%5,04%
Announcement Date 03/30/202003/29/202103/22/2022---
1 CNY in Million
2 CNY
Previous periodNext period
Estimates
Key data
Capitalization (CNY) 73 969 965 902
Capitalization (USD) 10 377 671 358
Net sales (CNY) 39 005 086 600
Net sales (USD) 5 472 247 622
Number of employees 36 604
Sales / Employee (CNY) 1 065 596
Sales / Employee (USD) 149 499
Free-Float 60,8%
Free-Float capitalization (CNY) 44 954 438 863
Free-Float capitalization (USD) 6 306 916 421
Avg. Exchange 20 sessions (CNY) 834 010 981
Avg. Exchange 20 sessions (USD) 117 008 191
Average Daily Capital Traded 1,13%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA